Sotyktu Dosage
Generic name: DEUCRAVACITINIB 6mg
Dosage form: tablet, film coated
Drug class: Multikinase inhibitors
Medically reviewed by Drugs.com. Last updated on Sep 9, 2022.
Recommended Evaluations and Immunizations Prior to Treatment Initiation
Evaluate patients for active and latent tuberculosis (TB) infection prior to initiating treatment with SOTYKTU. If positive, start treatment for TB prior to SOTYKTU use [see Warnings and Precautions (5.3)].
Update immunizations according to current immunization guidelines [see Warnings and Precautions (5.7)].
Recommended Dosage
The recommended dosage of SOTYKTU is 6 mg taken orally once daily, with or without food.
Do not crush, cut, or chew the tablets.
Recommended Dosage in Patients with Hepatic Impairment
SOTYKTU is not recommended in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].
No dosage adjustment is needed for patients with mild to moderate hepatic impairment.
Frequently asked questions
- Sotyktu vs Otezla: How do they compare?
- How long does it take for Sotyktu to work?
- How long can I take Sotyktu for?
- How is Sotyktu given / administered?
More about Sotyktu (deucravacitinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
